Journal of Cardiothoracic Surgery (Apr 2024)

Triple-induction treatment for locally advanced non-small cell lung cancer: a case report of pathological complete response

  • Raphael S. Werner,
  • Olivia Lauk,
  • Georg Tscherry,
  • Alessandra Curioni-Fontecedro,
  • Sylvia Höller,
  • Isabelle Opitz

DOI
https://doi.org/10.1186/s13019-024-02759-y
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Background In patients with resectable stage III non-small cell lung cancer (NSCLC), induction chemoimmunotherapy followed by surgical resection has shown unprecedented rates of pathological response and event-free survival. However, a triple-induction including radiochemotherapy and immunotherapy followed by surgical resection has not been routinely established in clinical practice. Case presentation We report the case of a 47-year-old patient with stage IIIA NSCLC who was treated in a combined concept including induction concurrent radiochemotherapy, followed by 4 cycles of pembrolizumab and subsequent intrapericardial left-sided pneumonectomy. Histological analysis revealed a pathological complete response. Conclusions The case demonstrates that the combination of neoadjuvant chemo-, radio- and immunotherapy in advanced NSCLC may lead to a relevant down-staging and may enable a R0-resection of a borderline resectable tumor. However, the combination of four different treatment modalities requires resilience and a good performance status. A triple induction treatment may be a promising option for selected patients with locally advanced NSCLC and good performance status.

Keywords